Marker Therapeutics unveils MultiTAA therapy data in pancreatic cancer

Pancreatic cancer remains as one of the most crucial and challenging solid tumor malignancies Marker Therapeutics Inc., a clinical stage immune-oncology company, has recently announced interim data from an ongoing investigator-sponsored clinical study, led by Baylor College of Medicine to evaluate the MultiTAA T cell therapy of the company in pancreatic adenocarcinoma patients. Sources familiar with the matter informed that during a plenary session, the data was examined recently in an oral presentation along with a poster presentation in San Francisco, U.S., at the American Association for Cancer Research’s Immune Cell Therapies for Cancer: Challenges and Successes of CAR T Cells and Other Forms of Adoptive Therapy conference, which was held from 19 July to 22 July 2019. According to Assistant Professor and lead investigator of Oncology at Baylor College of Medicine, Brandon G. Smaglo, M.D., FACP, pancreatic cancer remains as one of the most crucial and challenging to treat solid tumor malignancies and survival rates have not seen a significant improvement over 40 years. The institute is encouraged by the provisional data which propose that MultiTAA therapy may contribute to further durable responses without adding any kind of toxicity when used in combination with a second-line therapy or standard-of-care chemotherapy for chemo-refractory patients, Dr. Smaglo mentioned. According to Dr. Smaglo, instead of especially dense desmoplastic stroma encompassing pancreatic tumors, which has been measured to be a prime problem for T cell effectiveness, the study of patients with borderline surgically resectable disease proposes that MultiTAA cells are able to meaningfully infiltrate the tumor. Seemingly, the trial plans to register a total of 45 patients with borderline resectable pancreatic adenocarcinoma in a three-arm trial. Arm A is for patients with metastatic/unresectable disease who are greatly responding to standard first-line chemotherapy. While Arm B is for patients with therapy intolerance or progressive disease and Arm C is an experimental arm for the patients with surgically resectable disease. Source Credits: https://www.markertherapeutics.com/2019/07/marker-therapeutics-reports-interim-results-of-its-multitaa-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma-at-aacr/